SBIR/STTR Research Award
SBIR Phase I: A thermogel-based drug delivery platform for the upper gastrointestinal bleeding treatment
Award amount
$224,999Program and phase
SBIR · Phase IAward year
2020Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- INTACT THERAPEUTICS
- Proposal award date
- 2020-08-15
- Contract end date
- 2021-04-30
- UEI
- ZYZ1FU7HBU73
- Solicitation number
- Not reported
- Topic code
- BM
Research abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop an innovative method to treat upper gastrointestinal bleeding (UGIB). UGIB results in more than 550,000 hospitalizations per year in th
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- SBIR Phase II: A thermogel-based drug delivery platform for the upper gastrointestinal bleeding treatment
- A novel thermogel for topical treatment of ulcerative colitis with microbialmetabolite mimicry.
Research funding history
3 SBIR/STTR records share this UEI (2020–2024). Reported award amounts total $1,521,257. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: National Science Foundation, Department of Health and Human Services